Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...

Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...

April 6, 2026 • Higher education is especially reliant on computers and phones, but accessibility for people with disabilities has often been forgotten. A new federal rule could change that. March 30, ...